Similar articles

• Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.

  Graziano JH, Markenson A, Miller DR, Chang H, Bestak M, Meyers P, Pisciotto P, Rifkind A. Graziano JH, et al. J Pediatr. 1978 Apr;92(4):648-52. doi: 10.1016/s0022-3476(78)80315-1. J Pediatr. 1978. PMID: 633032 Clinical Trial. No abstract available.
• Iron chelation therapy with deferoxamine in Cooley anemia.

  Cohen A, Schwartz E. Cohen A, et al. J Pediatr. 1978 Apr;92(4):643-7. doi: 10.1016/s0022-3476(78)80314-x. J Pediatr. 1978. PMID: 633031
• Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.

  Weiner M, Karpatkin M, Hart D, Seaman C, Vora SK, Henry WL, Piomelli S. Weiner M, et al. J Pediatr. 1978 Apr;92(4):653-8. doi: 10.1016/s0022-3476(78)80316-3. J Pediatr. 1978. PMID: 633033 No abstract available.
• Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.

  Pippard MJ. Pippard MJ. Acta Haematol. 1987;78(2-3):206-11. doi: 10.1159/000205876. Acta Haematol. 1987. PMID: 3120473 Review.
• Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.

  Nienhuis AW, Delea C, Aamodt R, Bartter F, Anderson WF. Nienhuis AW, et al. Birth Defects Orig Artic Ser. 1976;12(8):177-85. Birth Defects Orig Artic Ser. 1976. PMID: 795481 Review. No abstract available.